Amryt Pharma Share Discussion Threads

[whatno] 08/9/2022 17:24

The problem is that Krystal has submitted their NDA in the US. Krystal's clinical results seemed to be far superior to Amryt's and they will likely be first to market in the largest pharma market in the world (USA)..

[punter6] 08/9/2022 17:00

Has everybody lost interest here?!

Some good news today with Filsuvez receiving marketing authorisation approval from the UK's MHRA.

[chica1] 20/7/2022 12:50

Confirmation of what we know already.

CORPORATE ACTION NOTICE Important information about your stock.
20 July 2022

A corporate action is taking place in relation to AMRYT PHARMA, which you currently hold in your portfolio (m. What is happening? Shares Deemed Worthless The Amryt Pharma FDA Contingent Value Rights have expired without the conditions being met for a payment to be made to shareholders. The FDA Contingent Value Rights have therefore been deemed worthless and will be removed from your account.

[gnnmartin] 23/6/2022 20:41

Thanks. A pity.

[onceaday] 23/6/2022 15:08

The CVR was awarded upon CHMP opinion not EC approval. But..it's only $5M in total.

[gnnmartin] 23/6/2022 14:58

European Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional EB.

Does this mean a payment on the contingent rights? Or is it too late for that?

[chica1] 22/6/2022 16:19

Where's AP103?

[richpassi] 05/6/2022 19:15

Good not could !

[richpassi] 05/6/2022 19:14

How could I say anything else ! Hope you could Pap ;)

[papillon] 05/6/2022 13:06

👍 richpassi 🤣🤣🤣🤣

[richpassi] 05/6/2022 10:41

I wouldn't ;) lol

[onceaday] 04/6/2022 15:29

Does Mrs Claris Bemedicta advise buying Amryt? 😄😄😄

[exfm] 04/6/2022 12:07

Just catching up on this; so this was from the announcement:The total amount payable to CVR Holders will be approximately USD$5.7million. Each CVR Holder will be issued with one loan note of USD$0.0995 for each CVR they hold (each a "Loan Note"). The certificates for the Loan Notes will be held by the Company's Registrar, Link Group ("Link"), in electronic form on behalf of each CVR Holder. So I assume this means that we will receive 9.95 USD cents for each CVR. This will actually arrive on the 14th September. Is this other peoples understanding? https://otp.tools.investis.com/clients/uk/amryt_pharmaceuticals_dac1/usn/usnews-story.aspx?cid=1375&newsid=83319

[onceaday] 19/5/2022 18:59

Oh great. That's worthless.in that case.

[40plus] 19/5/2022 17:38

Revenue CVR is also timebound:-

"A contingent entitlement of up to a maximum amount of $35,000,000 on Amryt achieving a 12-Month Trailing Net Product Revenue in excess of $75,000,000 from sales of AP101 prior to 30 June 2024"

[onceaday] 18/5/2022 16:53

There are three CVRs. EMA, FDA and $75M revenue.The first two are time-bound but I think revenue is not. Happy to be corrected.

[chica1] 18/5/2022 10:42

Well at least the $ is strong (and should be) when the time comes.
I'm surprised we're getting anything,I thought the CVR's were for FDA approval not EMA. I can't see the FDA changing their decision because I think there's been a fudge at the EMA as Episalvan already had Partial Thickness Wounds approval (which the FDA already rejected in 2016)

[onceaday] 17/5/2022 16:39

Ler's hope your broker will accept a dollar denominated cheque! :-)

[punter6] 17/5/2022 15:20

Great,we'll be able to buy a few rounds to celebrate so on 22nd September!!

[40plus] 08/5/2022 11:12

Near end of Q1 2022 Conf Call on 4th May, Rory Nealon advises EMA CVR to payout at approx 9.9 US Cents per CVR payable in around 4 Months time.

[onceaday] 04/5/2022 13:05

An even bigger loss than the same quarter last year. Cash pile shrinking... Will Amryt ever be profitable?

[bazworth] 26/4/2022 13:48

Onwards & upwards!